SCHEMBL3497947

SCHEMBL3497947

CN1CCC2(CCCN(C(=O)OC(C)(C)C)C2)C1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.49
GRIN2B Q13224 1/20 0.41
GRIN2C Q14957 1/20 0.41
HPGD P15428 1/20 0.39
HRH3 Q9Y5N1 4/20 0.39
USP2 O75604 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
MMP2 P08253 1/20 0.37
MMP13 P45452 1/20 0.37
MMP14 P50281 1/20 0.37
ADAM17 P78536 1/20 0.37
BACE1 P56817 2/20 0.36
CTSD P07339 1/20 0.36
NR1H2 P55055 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20474662 0.89 USP30 (0.47) USP30GRIN2BGRIN2CHPGDHRH3
SCHEMBL17082036 0.86 USP30 (0.49) USP30GRIN2BGRIN2CHPGDHRH3
SCHEMBL20569460 0.86 HRH3 (0.46) USP30GRIN2BGRIN2CHPGDHRH3
SCHEMBL31170164 0.84 USP30 (0.51) USP30GRIN2BGRIN2CHPGDHRH3
SCHEMBL1299378 0.84 USP2 (0.46) USP30HPGDHRH3USP2SMN1; SMN2
SCHEMBL3497285 0.84 USP30 (0.45) USP30GRIN2BGRIN2CHPGDHRH3
SCHEMBL3498966 0.83 ACACB (0.46) USP30HPGDHRH3KDM4EMAPT
SCHEMBL3499124 0.83 USP30 (0.47) USP30GRIN2BGRIN2CHPGDHRH3
SCHEMBL3497329 0.83 USP30 (0.47) USP30GRIN2BGRIN2CHPGDHRH3
SCHEMBL17371377 0.83 USP30 (0.41) USP30GRIN2BGRIN2CHPGDHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122858-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2012-05-17 US disclosed
US-8110581-B2 Lactam compounds and their use as pharmaceuticals INCYTE CORPORATION (US) 2012-02-07 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20090291946-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2009-11-26 US disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291946-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS HSD11B1, HSD11B2, HSD17B1 USP30 3259/4885GRIN2B 1196/4885GRIN2C 1342/4885
US-20100160255-A1 SPIRO-CYCLIC COMPOUND ACACA, CPT1B, PC USP30 3125/4885GRIN2B 4231/4885GRIN2C 3909/4885
US-20120122858-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS HSD11B1, HSD11B2, HSD17B1 USP30 3259/4885GRIN2B 1196/4885GRIN2C 1342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.